Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 665

Similar articles for PubMed (Select 19803538)

1.
2.

Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

McCullagh L, Walsh C, Barry M.

Pharmacoeconomics. 2012 Oct 1;30(10):941-59. doi: 10.2165/11591510-000000000-00000.

PMID:
22667458
3.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

4.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

PMID:
22187932
5.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ.

Clin Ther. 2009 Jan;31(1):194-212. doi: 10.1016/j.clinthera.2009.01.001.

PMID:
19243718
6.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.

Holmes M, Carroll C, Papaioannou D.

Pharmacoeconomics. 2012 Feb 1;30(2):137-46. doi: 10.2165/11591590-000000000-00000. Review.

PMID:
22185183
7.
8.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.

Holmes M, Carroll C, Papaioannou D.

Health Technol Assess. 2009 Sep;13 Suppl 2:55-62. doi: 10.3310/hta13suppl2/08. Review.

9.
10.

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.

McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, Ananthapavan J.

J Med Econ. 2012;15(5):817-28. doi: 10.3111/13696998.2012.684116. Epub 2012 Apr 24.

PMID:
22494267
11.

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

J Med Econ. 2011;14(6):824-34. doi: 10.3111/13696998.2011.623203. Epub 2011 Oct 24.

PMID:
22023098
12.

Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.

Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M.

Thromb Haemost. 2013 Nov;110(5):987-94. doi: 10.1160/TH12-12-0919. Epub 2013 Aug 22.

PMID:
23965805
13.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Burness CB, McKeage K.

Drugs. 2012 May 7;72(7):963-86. doi: 10.2165/11209080-000000000-00000. Review.

PMID:
22564134
14.

Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.

Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H.

Thromb Haemost. 2010 Oct;104(4):760-70. doi: 10.1160/TH10-01-0071. Epub 2010 Aug 30. Review.

PMID:
20806107
15.

New anticoagulants as thromboprophylaxis after total hip or knee replacement.

Hamidi V, Ringerike T, Hagen G, Reikvam Å, Klemp M.

Int J Technol Assess Health Care. 2013 Jul;29(3):234-43. doi: 10.1017/S0266462313000251. Epub 2013 Jun 17. Review.

PMID:
23768996
16.

[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].

Gómez Arrayas I, Suárez Fernández C, Gómez Cerezo JF, Betegón Nicolás L, de Salas-Cansado M, Rubio-Terrés C.

Rev Esp Salud Publica. 2012 Dec;86(6):601-12. doi: 10.4321/S1135-57272012000600006. Spanish.

17.

Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.

Postma MJ, Kappelhoff BS, van Hulst M, Brouwers JR.

J Med Econ. 2012;15(5):878-86. doi: 10.3111/13696998.2012.691144. Epub 2012 Jun 7.

PMID:
22563715
18.

[Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].

Gómez-Cerezo JF, Gómez-Arrayás I, Suárez-Fernández C, Betegón-Nicolás L, de Salas-Cansado M, Rubio-Terrés C.

Rev Esp Cir Ortop Traumatol. 2012 Nov-Dec;56(6):459-70. doi: 10.1016/j.recot.2012.07.009. Epub 2012 Sep 7. Spanish.

PMID:
23594943
19.

Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.

Haentjens P, De Groote K, Annemans L.

Arch Orthop Trauma Surg. 2004 Oct;124(8):507-17. Epub 2004 Sep 10.

PMID:
15365714
20.

Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.

Migliaccio-Walle K, Rublee D, Simon TA.

Postgrad Med. 2012 Jan;124(1):41-9. doi: 10.3810/pgm.2012.01.2516.

PMID:
22314113
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk